This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
Adam Feuerstein's Biotech Blog

Adam Feuerstein's Biotech Blog

Adam Feuerstein

Adam Feuerstein investigates the highly-speculative world of biotech stocks, and helps biotech investors avoid losing money.

To participate in Adam's "Biotech Stock Mailbag," please send your questions or comments using this form.

To chat with Adam on Twitter, click here.

Biotech Blog

Biotech columnist Adam Feuerstein answers readers' questions about health care.
8/22/14 8:48AM
Ampio Pharmaceuticals is blaming a mini Polar Vortex for blowing up a pivotal study of its osteoarthritis drug Ampion.
8/21/14 10:23AM
Mark Ahn's forced exit from the troubled Galena follows an internal investigation by the board.
8/21/14 7:16AM
Based on the positive study results, Amicus intends to seek European approval for migalastat early next year.
8/20/14 6:01AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
8/15/14 7:22AM
Contradictory statements made on whether or not Northwest Bio conducted an interim analysis of its DC-Vax phase III study.
8/14/14 10:20AM
Even in biotech where the "blue sky" potential for experimental drugs so often sends stock prices soaring, no company can escape the gravitational pull of balance sheets and income statements.
8/13/14 12:04PM
The announcement is short on specific details but the Arrowhead drug, ARC-520, appears to have passed through its first clinical hurdle in hepatitis B patients relatively well.
8/12/14 5:11PM
It's obvious DC-Vax came up futile in the early look at the phase III study data, leaving almost no chance the experimental cancer vaccine would benefit patients.
8/12/14 11:18AM
The struggling Provenge peddler is suffocating under $620 million in debt and the bill comes soon.
8/12/14 7:17AM
Intercept's OCA data look good. I don't see anything in the study results which scream, "RUN AWAY!" This is what some investors feared, causing the stock price to fall recently.
8/11/14 5:29PM
Retropin employees were using alias Twitter accounts -- two of which affected the persona of gangster rappers -- to promote Retrophin and pitch short-sale recommendations of other stocks to followers.
8/11/14 8:00AM
For all the hype about Afrezza's greatness, Mann walks away with a joint venture in which he secures just one-third of Afrezza's potential profit -- and losses.
8/11/14 6:49AM
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.
8/6/14 12:07PM
CNN reports competing, secret Ebola therapy already saved lives of U.S. aid workers.
8/4/14 10:07AM
In order to enroll the remaining 648 patients into the Multikine study by the end of 2015, Cel-Sci needs to average 40.5 patients per month, or 121.5 patients per quarter.
8/1/14 11:11AM
Biotech columnist Adam Feuerstein answers readers' questions about health care.
8/1/14 8:06AM
If an FDA appeal decision goes in Amarin's favor, the stock is moving much higher.
7/31/14 9:02AM
Aegerion offers brighter-than-expected sales outlook; Sarepta up on FDA response to petition.
7/30/14 11:22AM
Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.
7/29/14 10:26AM
Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.
7/28/14 12:34PM
Express Scripts and CVS Caremark are the largest and second-largest pharmacy benefits managers in the U.S. Both have been aggressive with efforts to rein in ever-escalating drug prices.
7/28/14 10:56AM
AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.
7/28/14 9:44AM
MannKind must report second-quarter financials before the end of the second week in August, which sets a quasi-deadline for Afrezza partner plans.
7/25/14 11:30AM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,013.00 -26.49 -0.16%
S&P 500 1,990.26 -2.11 -0.11%
NASDAQ 4,538.3890 +6.2850 0.14%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs